Paroxysmal Nocturnal Hemoglobinuria (PNH)
Institution
University of Maryland Greenebaum Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Dr. Niyongere joined the School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center as an Assistant Professor in 2018. Her clinical focus is in acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms and bone marrow failure syndromes. Dr. Niyongere’s primary research interests are in finding new therapeutic targets by understanding oncogenic signaling pathways involved in AML and MDS as well as studying the role of the tumor microenvironment in the development of chemoresistance in leukemia. Dr. Niyongere also serves as an attending physician on the
James Cook, MD, PhD
Institution
Cleveland Clinic, Learner School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
Pediatric
About
James R. Cook, M.D., Ph.D., is a Professor of Pathology at the Cleveland Clinic Lerner College of Medicine. He serves as Section Head of Hematopathology in the Department of Laboratory Medicine. Dr. Cook's clinical interests focus on diagnostic hematopathology and molecular diagnostics. His research interests include diagnostic and prognostic markers in non-Hodgkin lymphoma and plasma cell disorders, and molecular diagnosis of leukemia and lymphoma. He participates in numerous multi-institutional research efforts including the Lymphoma and Leukemia Molecular Profiling Project (LLMPP) and the
Chronic Kidney Disease and PNH
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Ramy M. Hanna, MD, FASN, FACP
Dr. Ramy Hanna is an Assistant Clinical Professor of Medicine and Nephrology at the University of California Irvine UCI-Health. He is a clinician-educator who works at the intersection of patient education and research, participating in ongoing research into diseases of the…
Living with PNH: A Patient Panel Discussion
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Join AAMDSIF's Leigh Clark for a panel discussion with two longer-term PNH patients, Marlena Connor and Jessi Hackney. Marlena and Jessi talk about their experiences as patients, what they wish they'd knowns when they were being diagnosed, what resources are important to them and…
We Made It! – Kristy Shares her Perspective in January 2021
We made it to another treatment day without anyone in our family getting sick! The week leading to treatment day has become pretty worrisome for me. What if someone in our family gets sick with or is exposed to COVID? Josh will not be able to get his infusion within the treatment window and then what? The questions I never thought I'd have to wonder about.
Is blood transfusion safe during the COVID-19 pandemic?
The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems to re-organize the management of patients in a short period. The causative pathogen of this pandemic is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of seven coronaviruses that can be found in humans. It is a rapidly mutating, enveloped, ssRNA, beta-coronavirus. The initial reports published after the pandemic spread showed a transmissibility rate of 2.2 and possibly low values of dispersion.
Severe Aplastic Anemia and PNH Diagnoses Came out of Nowhere - Marianna's Story
As a typical community college student, Mariana was busy. Classes, studying, day trips, all were part of her life. Yet during one shower, she dropped to the floor, suddenly dizzy. A few weeks later she would be out of breath, with unusual bruises on her skin.
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
Ravulizumab every 8 weeks showed non-inferiority to
eculizumab
eculizumab:
Eculizumab (Soliris ®) is given as an IV into a vein at the doctor’s office or at a special center.
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria
While red blood cells (RBCs) and granulocytes have been more studied, platelets and reticulocytes are not commonly used in
paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
The
complement system
complement system:
A group of proteins that move freely in the bloodstream.
